Literature DB >> 22654441

T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection.

Yukihiro Shimizu.   

Abstract

Hepatitis B is caused by the host immune response and T cells play a major role in the immunopathogenesis. More importantly, T cells not only destroy hepatocytes infected by hepatitis B virus (HBV), but also control HBV replication or eradicate HBV in a noncytolytic manner. Therefore, analysis of T cell immune response during acute and chronic HBV infection is important to develop a strategy for successful viral control, which could lead to immunotherapy for terminating persistent HBV infection. There have been many attempts at immunotherapy for chronic HBV infection, and some have shown promising results. High viral load has been shown to suppress antiviral immune responses and immunoinhibitory signals have been recently elucidated, therefore, viral suppression by nucleos(t)ide analogs, stimulation of antiviral immune response, and suppression of the immunoinhibitory signals must be combined to achieve desirable antiviral effects.

Entities:  

Keywords:  Hepatitis B virus infection; Immunopathogenesis; Immunotherapy; T cells

Mesh:

Year:  2012        PMID: 22654441      PMCID: PMC3360442          DOI: 10.3748/wjg.v18.i20.2443

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  77 in total

Review 1.  Th17 cells: the emerging reciprocal partner of regulatory T cells in the liver.

Authors:  Li Zhao; De Kai Qiu; Xiong Ma
Journal:  J Dig Dis       Date:  2010-06       Impact factor: 2.325

2.  Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers.

Authors:  Jin Luo; Jun Li; Rui L Chen; Lei Nie; Jie Huang; Zheng W Liu; Lin Luo; Xiao J Yan
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

3.  Combination therapy with antiviral drugs and hepatitis B vaccine in incidentally-detected and asymptomatic chronic hepatitis virus B carriers at Bangladesh.

Authors:  Mamun Al-Mahtab; Salimur Rahman; Sheikh Mohammad Fazle Akbar; Sakirul Islam Khan; Helal Uddin; Fazal Karim; Faroque Ahmed
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

4.  Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection.

Authors:  Xue-Ping Nan; Ye Zhang; Hai-Tao Yu; Yu Li; Rui-Lin Sun; Jiu-Ping Wang; Xue-Fan Bai
Journal:  Viral Immunol       Date:  2010-02       Impact factor: 2.257

5.  HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.

Authors:  Suna Wang; Qunying Han; Ni Zhang; Jinghong Chen; Zhengwen Liu; Guoyu Zhang; Zhu Li
Journal:  Immunol Lett       Date:  2009-10-31       Impact factor: 3.685

6.  Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B.

Authors:  Ji-Yuan Zhang; Zheng Zhang; Fang Lin; Zheng-Sheng Zou; Ruo-Nan Xu; Lei Jin; Jun-Liang Fu; Feng Shi; Ming Shi; Hui-Fen Wang; Fu-Sheng Wang
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

7.  Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial.

Authors:  Andrea M Woltman; Martijn J Ter Borg; Rekha S Binda; Dave Sprengers; B Mary E von Blomberg; Rik J Scheper; Kunihiko Hayashi; Nobusuke Nishi; André Boonstra; Renate van der Molen; Harry L A Janssen
Journal:  Antivir Ther       Date:  2009

8.  Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection.

Authors:  Hakan Senturk; Fehmi Tabak; Resat Ozaras; Levent Erdem; Billur Canbakan; Ali Mert; Ibrahim Yurdakul
Journal:  Dig Dis Sci       Date:  2008-11-19       Impact factor: 3.199

9.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

Authors:  Paola Fisicaro; Caterina Valdatta; Marco Massari; Elisabetta Loggi; Elisabetta Biasini; Luca Sacchelli; Maria Cristina Cavallo; Enrico M Silini; Pietro Andreone; Gabriele Missale; Carlo Ferrari
Journal:  Gastroenterology       Date:  2009-09-30       Impact factor: 22.682

View more
  22 in total

1.  CD8+ T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress.

Authors:  George F Gao; Jingmin Zhao; Yu Zhang; Yan Wu; Mengmeng Deng; Dongping Xu; Xiaodong Li; Zhihui Xu; Jun Hu; Han Zhang; Kefang Liu; Yingze Zhao; Feng Gao; Shengli Bi; William J Liu; Songdong Meng
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

2.  Influence of chronic HBV infection on superimposed acute hepatitis E.

Authors:  Si-Hong Cheng; Li Mai; Feng-Qin Zhu; Xing-Fei Pan; Hai-Xia Sun; Hong Cao; Xin Shu; Wei-Min Ke; Gang Li; Qi-Huan Xu
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

3.  Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.

Authors:  Q Zheng; Y Y Zhu; J Chen; Y B Ye; J Y Li; Y R Liu; M L Hu; Y C Zheng; J J Jiang
Journal:  Clin Exp Immunol       Date:  2015-04-12       Impact factor: 4.330

Review 4.  Genetic variation of hepatitis B virus and its significance for pathogenesis.

Authors:  Zhen-Hua Zhang; Chun-Chen Wu; Xin-Wen Chen; Xu Li; Jun Li; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  New horizon for radical cure of chronic hepatitis B virus infection.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Hepatol       Date:  2016-07-28

Review 6.  Immunopathogenesis of chronic hepatitis B.

Authors:  Irina P Balmasova; Nikolay D Yushchuk; Ospan A Mynbaev; Nageswara R Alla; Elena S Malova; Zhongjie Shi; Chang-Lu Gao
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

7.  Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.

Authors:  Yang Zhang; Xiao-Yu Hu; Sen Zhong; Fang Yang; Tao-You Zhou; Guo Chen; Yan-Yan Wang; Jian-Xing Luo
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

8.  An OX40/OX40L interaction directs successful immunity to hepatitis B virus.

Authors:  Jean Publicover; Anuj Gaggar; Jillian M Jespersen; Ugur Halac; Audra J Johnson; Amanda Goodsell; Lia Avanesyan; Stephen L Nishimura; Meghan Holdorf; Keith G Mansfield; Joyce Bousquet Judge; Arya Koshti; Michael Croft; Adil E Wakil; Philip Rosenthal; Eric Pai; Stewart Cooper; Jody L Baron
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

9.  Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China.

Authors:  Yao He; Pingping Xu; Yujun Chen; Rongping Yang; Baili Chen; Zhirong Zeng; Minhu Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.